Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Wit, M. C.Y.
Right arrow Articles by van den Bent, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Wit, M. C.Y.
Right arrow Articles by van den Bent, M. J.
Related Collections
Right arrow MRI
Right arrow All Oncology
Right arrow Primary brain tumor
Right arrow Radiation therapy-tumor
Right arrowRelated Article
NEUROLOGY 2004;63:535-537
© 2004 American Academy of Neurology
Brief Communications

Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression

M. C.Y. de Wit, MD, H. G. de Bruin, MD, W. Eijkenboom, MD, P. A.E. Sillevis Smitt, MD PhD and M. J. van den Bent, MD PhD

From the Departments of Neuro-oncology/Neurology (Drs. de Wit, Sillevis Smitt, and van den Bent), Radiology (Dr. de Bruin), and Radiotherapy (Dr. Eijkenboom), Daniel den Hoed Cancer Center/Erasmus Medical Center, Rotterdam, The Netherlands.

Address correspondence and reprint requests to Dr. M.J. van den Bent, Department of Neuro-oncology/Neurology, Daniel den Hoed Cancer Center/Erasmus Medical Center, PO Box 5201, 3008 AE Rotterdam, The Netherlands; e-mail: m.vandenbent{at}erasmusmc.nl

To determine the frequency of progressive MRI lesions shortly after radiotherapy for glioma with spontaneous improvement or stabilization, the authors studied a cohort of patients treated within two prospective phase III trials with radiotherapy only. In 9 out of 32 patients, the first post-radiotherapy MRI showed progressive enhancement. In 3 of these 9 the MRI improved or stabilized for 6 months without additional treatment. The authors conclude that patients with progressive lesions within 3 months after radiotherapy should not be eligible for phase II trials on recurrent glioma.

Received December 4, 2003. Accepted in final form April 13, 2004.

See Commentary, page 407


Related Article

August 10 Highlight and Commentary
Neurology 2004 63: 407. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 JCOHome page
J. L. Clarke, F. M. Iwamoto, J. Sul, K. Panageas, A. B. Lassman, L. M. DeAngelis, A. Hormigo, C. P. Nolan, I. Gavrilovic, S. Karimi, et al.
Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma
J. Clin. Oncol., August 10, 2009; 27(23): 3861 - 3867.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. van den Bent, M. A. Vogelbaum, P. Y. Wen, D. R. Macdonald, and S. M. Chang
End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria
J. Clin. Oncol., June 20, 2009; 27(18): 2905 - 2908.
[Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
S.-I. Miyatake, S. Kawabata, N. Nonoguchi, K. Yokoyama, T. Kuroiwa, H. Matsui, and K. Ono
Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas
Neuro-oncol, January 1, 2009; 11(4): 430 - 436.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
S. M. Chang, J. Clarke, and P. Wen
Novel Imaging Response Assessment for Drug Therapies in Recurrent Malignant Glioma
ASCO Educational Book, January 1, 2009; 2009(1): 107 - 111.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. C. Chamberlain
Pseudoprogression in Glioblastoma
J. Clin. Oncol., September 10, 2008; 26(26): 4359 - 4359.
[Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
R. I. Jakacki, A. Yates, S. M. Blaney, T. Zhou, R. Timmerman, A. M. Ingle, L. Flom, M. D. Prados, P. C. Adamson, and I. F. Pollack
A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood
Neuro-oncol, August 1, 2008; 10(4): 569 - 576.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. A. Brandes, E. Franceschi, A. Tosoni, V. Blatt, A. Pession, G. Tallini, R. Bertorelle, S. Bartolini, F. Calbucci, A. Andreoli, et al.
MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients
J. Clin. Oncol., May 1, 2008; 26(13): 2192 - 2197.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
A. A. Brandes, A. Tosoni, F. Spagnolli, G. Frezza, M. Leonardi, F. Calbucci, and E. Franceschi
Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology
Neuro-oncol, January 1, 2008; 10(3): 361 - 367.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. C. Chamberlain, W. B. Pope, and T. Cloughesy
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
Neurology, December 12, 2006; 67(11): 2089 - 2089.
[Full Text] [PDF]

Home page
 NeurologyHome page
W. Wick and A. Kaufmann
Glioblastoma: what's ischemia got to do with it?
Neurology, November 14, 2006; 67(9): 1540 - 1541.
[Full Text] [PDF]

Home page
 NeurologyHome page
F. Schmidt, J. Fischer, U. Herrlinger, K. Dietz, J. Dichgans, and M. Weller
PCV chemotherapy for recurrent glioblastoma
Neurology, February 28, 2006; 66(4): 587 - 589.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.